GlassScriptPhysician profile
Robert Craig Martin
NPI 1225020399
$6,747.36
in general payments reported to CMS, 2019-2025
51 companies · $738 in 2025
The $738 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $919 · 2021: $1,248 · 2022: $1,010 · 2023: $984 · 2024: $924 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,646.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $883.41 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $655.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $487.52 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $424.39 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $362.68 | 2019-2024 | Xifaxan |
| Abbvie INC. | $347.88 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $338.46 | 2019-2022 | |
| Amgen INC. | $306.43 | 2019-2024 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $290.81 | 2019-2025 | Airsupra |
| Pfizer INC. | $244.53 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $160.82 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $159.67 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $144.56 | 2019-2022 | |
| Esperion Therapeutics, INC. | $116.51 | 2020-2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $115.40 | 2019-2024 | Rexulti |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.